Guselkumab (GUS) clinical trials

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

This study looks at how quickly different treatments for Crohn's disease, like vedolizumab and others, start working. We want to understand if vedolizumab actually takes longer to reduce symptoms than other medicines, using patient feedback as key information.